ClearPoint Neuro CLPT
- Market cap
- $318.9M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 7.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $45.5M
- +33% on a year ago
- Net margin
- −79.4%
- Free cash flow yield
- −10.4%
ClearPoint Neuro trades at 7.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $45.5M over the last twelve months, up 33% on a year earlier with a −79% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $6.8M+32% | $7.6M+41% | $7.9M+32% | $8.1M+41% | $7.8M+14% | $8.5M+11% | $9.2M+17% | $8.9M+9% | $10.4M+34% | $12.1M+43% | $10.9M+18% | $12.1M+36% | |
| Cost of revenue | $2.8M+55% | $3.1M+40% | $2.9M+2% | $3.3M+32% | $3M+8% | $3.4M+8% | $3.7M+28% | $3.3M−0% | $4M+33% | $4.4M+30% | $4.2M+14% | $5M+54% |
| Gross profit | $4M+19% | $4.5M+41% | $5M+60% | $4.8M+48% | $4.8M+19% | $5.1M+13% | $5.6M+11% | $5.6M+16% | $6.4M+35% | $7.8M+51% | $6.7M+21% | $7.1M+26% |
| R&D | $2.7M−9% | $2.6M−13% | $3.1M−14% | $3.3M+37% | $3.3M+26% | $3.4M+29% | $3.8M+23% | $3.5M+4% | $3.2M−3% | $4.5M+34% | $4.6M+21% | $4M+16% |
| SG&A | $2.7M+15% | $2.8M−5% | $2.8M−13% | $3.1M+8% | $3.3M+20% | $4.1M+44% | $3.4M+23% | $3.6M+14% | $5.4M+67% | $5M+22% | $5.6M+64% | $3.8M+7% |
| −$4.7M+5% | −$4.2M−26% | −$4.7M−34% | −$5.2M+5% | −$5.6M+20% | −$6.2M+46% | −$5.7M+20% | −$5.3M+2% | −$7M+25% | −$8.5M+38% | −$10.2M+80% | −$6.3M+20% | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | $0 | $365K | $939K | $1.1M | $1.4M | $1.4M+287% | $1.4M+54% |
| Pre-tax income | n/a | −$4.1M | −$4.4M | −$5M | −$5.4M | −$6M+45% | −$5.8M+32% | −$5.9M+19% | −$7.8M+44% | −$9.5M+59% | −$11.4M+96% | −$7.5M+27% |
| n/a | $15K | $15K | $14K | −$32K | $18K+20% | $25K+67% | $8K−43% | $4K | $8K−56% | −$38K | −$4K | |
| Net income | −$4.6M+5% | −$4.1M−26% | −$4.4M−38% | −$5M+3% | −$5.4M+17% | −$6M+45% | −$5.8M+32% | −$5.9M+18% | −$7.8M+45% | −$9.6M+59% | −$11.3M+94% | −$7.5M+27% |
| −$0.19+6% | −$0.16−30% | −$0.16−45% | −$0.18−10% | −$0.20+5% | −$0.22+38% | −$0.21+31% | −$0.21+17% | −$0.27+35% | −$0.32+46% | −$0.38+81% | −$0.24+14% | |
| 24.6M+0% | 25.5M+4% | 27.5M+12% | 27.6M+12% | 27.6M+12% | 27.7M+9% | 28.3M+3% | 28.4M+3% | 28.8M+5% | 29.5M+7% | 30.2M+7% | 31M+9% |
Gross profit: 38 periods, Q1 FY11 to Q1 FY21: not printed by the filing, worked out from its own lines.
EPS, diluted: 15 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 15 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest ClearPoint Neuro's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CLPTClearPoint Neuro | $318.9M | n/m | n/a | 7.0× | +33% | −79.4% | |
| EMBCEmbecta | $350.7M | 4.2× | 11.6× | 0.3× | −8% | 8.6% | |
| INFUInfuSystem | $275.7M | 33.8× | 43.5× | 1.9× | +2% | 6.0% | |
| UTMDUtah Medical Products | $224.6M | 21.5× | 20.9× | 6.2× | −7% | 29.0% | |
| TCMDTactile Systems Technology | $518.1M | 21.2× | 62.3× | 1.5× | +17% | 7.1% | |
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| MOVMovado | $710.9M | 17.7× | 13.4× | 1.0× | +5% | 6.0% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| KEQUKewaunee Scientific | $96.7M | 12.1× | 13.6× | 0.3× | +5% | 3.0% | |
| IARTIntegra Lifesciences | $1.1B | 80.1× | 46.3× | 0.6× | +1% | 0.8% | |
| BVSBioventus | $1.1B | 17.1× | 27.1× | 1.9× | +4% | 9.4% | |
| Peer median | $434.4M | 19.4× | 24.0× | 1.7× | +5% | 7.8% |
More on ClearPoint Neuro
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .